ArticleCancer drug resistance (Alhambra, Calif.)2022

Combating CHK1 resistance in triple negative breast cancer: EGFR inhibition as potential combinational therapy.

Casey D Stefanski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.